MC-339 / Novartis - LARVOL DELTA

MC339, a novel radiopharmaceutical, targets DLL3-expressing cancers of different tissue origins (EORTC-NCI-AACR 2024) - "Taken together, these studies support further investigation of the radiolabeled MC339 as a novel therapeutic for patients with DLL3-expressing solid tumors."

Endocrine Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3

Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers (ESMO 2024) - "Taken together, these studies support further investigation of the novel therapeutic MC339 as a treatment for patients with DLL3-expressing solid tumors."

Preclinical • Endocrine Cancer • Genito-urinary Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer (Businesswire) - "Mariana Oncology...announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis....The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer."

M&A • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Mariana Oncology Announces $175 Million Series B Financing (Businesswire) - "Mariana Oncology Inc...today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion....Proceeds from the financing will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization....'The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing.'"

Financing • New trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer